GlassScriptPhysician profile
Trushar B Patel
NPI 1639378599
$48,754.32
in general payments reported to CMS, 2019-2025
23 companies · $861 in 2025
The $861 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $24K · 2020: $16K · 2021: $1,468 · 2022: $4,613 · 2023: $592 · 2024: $728 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Education: $25.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,154.91 |
| Education | $25.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24,624.16 | 2019-2024 | |
| Abbvie INC. | $20,039.85 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,832.20 | 2019-2025 | Xifaxan, Trulance |
| Imperative Care, INC | $197.87 | 2025 | Symphony Catheter |
| Intercept Pharmaceuticals, INC. | $193.76 | 2019-2025 | Ocaliva |
| Boston Scientific Corporation | $142.83 | 2025 | Therasphere360_pi |
| Ferring Pharmaceuticals INC. | $113.78 | 2025 | Adstiladrin |
| Lilly USA, LLC | $102.33 | 2024 | Omvoh |
| Takeda Pharmaceuticals U.S.A., INC. | $79.50 | 2023-2024 | Entyvio |
| Genzyme Corporation | $69.11 | 2024-2025 | |
| Mallinckrodt Hospital Products INC. | $57.46 | 2023-2024 | Terlivaz |
| Celltrion USA INC. | $51.58 | 2024-2025 | Vegzelma, Yuflyma, Zymfentra |
| Janssen Biotech, INC. | $49.14 | 2023-2024 | Stelara |
| Phathom Pharmaceuticals, INC. | $39.02 | 2023-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $36.91 | 2023-2025 | Dupixent |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $20.24 | 2025 | Rezdiffra |
| Novo Nordisk INC | $19.42 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $18.29 | 2023 | Linzess |
| Ardelyx, INC. | $15.14 | 2025 | Ibsrela |
| Dova Pharmaceuticals | $14.80 | 2021 | |
| Celgene Corporation | $14.53 | 2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $11.92 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $10.48 | 2024 | Lockado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trushar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.